TAOK3 and breast cancer: This study also revealed that TAOK3 enhanced microtubule-targeted drug (paclitaxel, eribulin, and vinorelbine) resistance via the NF-κB signaling pathway in breast cancer cell lines [53] and suggested that disrupting the interaction between TAOK3 and NF-κB signaling may have beneficial therapeutic effects for breast cancer patients treated with anti-microtubule agents.